Compare Stocks → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:AMARNASDAQ:ATXINASDAQ:BLPHNASDAQ:BNTCNASDAQ:EYEG Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMARAmarillo Biosciences$0.60$0.05▼$1.97$25.24M-0.0618,253 shs6,100 shsATXIAvenue Therapeutics$0.15$0.15$0.11▼$1.36$6.75M-0.255.55 million shs491,951 shsBLPHBellerophon Therapeutics$0.06$0.06$0.03▼$12.58$695K0.6771,541 shs1,066 shsBNTCBenitec Biopharma$5.13+3.4%$3.91$1.86▼$9.01$13.29M1.0215,157 shs3,987 shsEYEGAB Corporate Bond ETF$35.73+0.4%$1.90$1.44▼$8.18$450.85M0.81935,975 shs1 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMARAmarillo Biosciences0.00%0.00%0.00%0.00%0.00%ATXIAvenue Therapeutics+1.06%-3.66%+3.81%-6.32%-85.60%BLPHBellerophon Therapeutics-1.60%+11.18%+6.69%+67.10%-99.24%BNTCBenitec Biopharma+3.43%-5.87%+21.28%+55.93%+56.92%EYEGAB Corporate Bond ETF+0.43%+0.71%+1.31%-0.98%+1,732.20%[BUY ALERT] Our #1 A.I. Stock for March (Ad)It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.Get the name of the stock here - before it takes off >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMARAmarillo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AATXIAvenue Therapeutics3.433 of 5 stars3.53.00.04.61.20.00.0BLPHBellerophon Therapeutics1.2035 of 5 stars3.20.00.04.80.00.00.6BNTCBenitec Biopharma2.8208 of 5 stars3.55.00.00.03.70.80.0EYEGAB Corporate Bond ETFN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMARAmarillo BiosciencesN/AN/AN/AN/AATXIAvenue Therapeutics3.00Buy$32.0020,869.86% UpsideBLPHBellerophon Therapeutics2.33Hold$2.003,420.20% UpsideBNTCBenitec Biopharma3.00Buy$10.0094.93% UpsideEYEGAB Corporate Bond ETFN/AN/AN/AN/ACurrent Analyst RatingsLatest BLPH, AMAR, EYEG, ATXI, and BNTC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/15/2024BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $10.001/24/2024BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$6.00 ➝ $8.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMARAmarillo Biosciences$20K0.00N/AN/A($0.03) per share0.00ATXIAvenue TherapeuticsN/AN/AN/AN/A$0.03 per shareN/ABLPHBellerophon TherapeuticsN/AN/AN/AN/A$0.27 per shareN/ABNTCBenitec Biopharma$80K166.08N/AN/A$0.12 per share42.75EYEGAB Corporate Bond ETF$10K45,085.04N/AN/A$1.26 per share28.36Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMARAmarillo Biosciences-$1.45MN/A0.00N/AN/A-41,453.98%N/A-574.29%N/AATXIAvenue Therapeutics-$10.38M-$1.27N/A∞N/AN/AN/A-335.11%5/10/2024 (Estimated)BLPHBellerophon Therapeutics-$19.83M-$0.84N/A∞N/AN/A-187.35%-104.97%3/29/2024 (Estimated)BNTCBenitec Biopharma-$19.56MN/A0.00∞N/AN/A-204.34%-142.81%5/20/2024 (Estimated)EYEGAB Corporate Bond ETF-$8.09M-$1.68N/AN/AN/AN/A-104.96%-60.03%N/ALatest BLPH, AMAR, EYEG, ATXI, and BNTC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024N/ABLPHBellerophon TherapeuticsN/A-$0.42-$0.42N/AN/AN/A2/13/2024Q2 2024BNTCBenitec BiopharmaN/A-$2.64-$2.64-$2.64N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMARAmarillo BiosciencesN/AN/AN/AN/AN/AATXIAvenue TherapeuticsN/AN/AN/AN/AN/ABLPHBellerophon TherapeuticsN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/AEYEGAB Corporate Bond ETFN/AN/AN/AN/AN/ALatest BLPH, AMAR, EYEG, ATXI, and BNTC DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/29/2024EYEGAB Corporate Bond ETFMonthly$0.14863/1/20243/4/20243/7/20241/31/2024EYEGAB Corporate Bond ETFMonthly$0.14762/1/20242/2/20242/7/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMARAmarillo BiosciencesN/A0.030.07ATXIAvenue TherapeuticsN/A1.551.55BLPHBellerophon TherapeuticsN/A3.963.96BNTCBenitec Biopharma0.013.623.62EYEGAB Corporate Bond ETF0.013.073.07OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMARAmarillo BiosciencesN/AATXIAvenue Therapeutics17.34%BLPHBellerophon Therapeutics10.61%BNTCBenitec Biopharma52.19%EYEGAB Corporate Bond ETF64.16%Insider OwnershipCompanyInsider OwnershipAMARAmarillo Biosciences34.35%ATXIAvenue Therapeutics1.80%BLPHBellerophon Therapeutics5.20%BNTCBenitec Biopharma4.30%EYEGAB Corporate Bond ETF58.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAMARAmarillo Biosciences242.07 millionN/ANot OptionableATXIAvenue Therapeutics344.26 million43.46 millionNot OptionableBLPHBellerophon Therapeutics1812.23 million11.60 millionOptionableBNTCBenitec Biopharma182.59 million2.48 millionNo DataEYEGAB Corporate Bond ETF1412.62 million5.28 millionNot OptionableBLPH, AMAR, EYEG, ATXI, and BNTC HeadlinesSourceHeadlineBHG Financial Completes First Consumer-Only ABS Transaction, Closes Over $273M in ABS Notesmarkets.businessinsider.com - March 26 at 9:47 AMInvesco BulletShares 2029 Corporate Bond ETF declares monthly distribution of $0.0619msn.com - March 19 at 7:42 AMAMC Entertainment Tops The List Of High-Yielding Corporate Bonds — A Look At Yields As Bond Appetites Growmsn.com - March 18 at 3:48 PMCompare with VictoryShares Corporate Bond ETF (UCRD)msn.com - February 25 at 1:31 PMInvesco BulletShares 2024 Corporate Bond ETF declares monthly distribution of $0.0544msn.com - February 20 at 7:43 AMInvesco BulletShares 2024 Corporate Bond ETF declares monthly distribution of $0.0521msn.com - January 22 at 3:16 PMInvesco BulletShares 2027 Corporate Bond ETF declares monthly distribution of $0.0683msn.com - December 18 at 2:17 PMUS Corporate Bond Issuance Seen Increasing After Yields Slidemsn.com - December 18 at 7:46 AMiShares ESG Aware 1-5 Year USD Corporate Bond ETF declares monthly distribution of $0.0654msn.com - December 16 at 6:37 PMTFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directorsfinance.yahoo.com - November 30 at 8:37 AMKiora Pharmaceuticals (KPRX) Receives a Buy from Maxim Groupmarkets.businessinsider.com - September 15 at 3:15 PMEarum Pharmaceuticals share pricelivemint.com - September 12 at 3:19 AMH.C. Wainwright Sticks to Their Buy Rating for Kiora Pharmaceuticals (KPRX)markets.businessinsider.com - August 24 at 6:49 AMSUNPHARMA.NS - Sun Pharmaceutical Industries Limitedfinance.yahoo.com - July 28 at 8:22 PMOcular Drug Delivery System Market sales will total US$ 27.82 Billion by 2031 | Says Future Market Insightspharmiweb.com - May 16 at 10:52 PMS-1: KIORA PHARMACEUTICALS INCmarketwatch.com - May 6 at 9:38 AMMaxim Group Sticks to Their Buy Rating for Kiora Pharmaceuticals (KPRX)markets.businessinsider.com - April 29 at 3:37 PMOcular Inflammation Treatment Market Facts and Figures By 2030marketwatch.com - April 18 at 11:07 PMDry Eye Medication Market Average Price by Manufacturersmarketwatch.com - March 30 at 12:36 AMUveitis Treatment Market Growth and Forecast till 2028marketwatch.com - March 23 at 7:35 AMDry Eye Medication Market is Booming in Near Future 2023-2028marketwatch.com - March 8 at 10:01 PMThe Future of Ocular Inflammation Treatment Market (2023-2028)-Worldwide Insights and Predictionsmarketwatch.com - March 3 at 4:51 AMA timeline of Akorn Pharmaceuticals in Decaturherald-review.com - February 24 at 11:51 PMOcular Drug Delivery Market Latest Research Report with Growth Projection and top Industry Analysis 2023-2028marketwatch.com - February 6 at 4:55 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAmarillo BiosciencesOTCMKTS:AMARAmarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.Avenue TherapeuticsNASDAQ:ATXIAvenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.Bellerophon TherapeuticsNASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Benitec BiopharmaNASDAQ:BNTCBenitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.AB Corporate Bond ETFNASDAQ:EYEGEyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.